Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B

ACCENDRA HEALTH INC/VA/

Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.
Pro forma 2024 revenue $2.68B (vs $10.7B reported); net loss pro forma $366.5M vs $362.7M.
Pro forma diluted EPS: 2024 -$4.78, 2023 -$0.15, 2022 -$0.72.
Amended Receivables Sale Program: sold $94M eligible receivables, removed $160M intercompany payable.
Retained a 5% equity interest in buyer with potential for up to $200M of priority distributions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.